How does wegovy's dosage compare to ozempic s?

What's the typical dosage for Wegovy and Ozempic?

WeGovy, also known as semaglutide, is a medication used to treat obesity, whereas Ozempic, also semaglutide, is primarily used to manage type 2 diabetes [1]. Both medications belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists.

The typical dosage for WeGovy when used for obesity treatment is 2.4 mg administered subcutaneously once a week, given in 20 minutes or less, at least 30 minutes before the first meal of the day, for chronic weight management with or without weight loss, in adult patients with initial body mass index (BMI) of 30 kg/m² or higher, or 27 kg/m² or higher in the presence of at least one weight-related condition (comorbidities) [2].

In contrast, the typical dosage for Ozempic when used for type 2 diabetes treatment is 1.0 mg administered subcutaneously once a week for 4 weeks, then increased to 1.0 mg or 1.5 mg, according to the individual patient's needs [3].

Why the difference in dosages?

The difference in dosages between the two uses might be due to the varying targets and mechanisms of action for obesity and diabetes treatment. WeGovy's dosage is higher compared to Ozempic, possibly due to its higher potency in promoting weight loss. On the other hand, Ozempic focuses on improving glycemic control and is less potent in promoting weight loss [4].

What happens if I'm switching from Ozempic to WeGovy?

Patients switching from Ozempic to WeGovy should start by taking 1.0 mg WeGovy for 1 week before increasing to the target dose of 2.4 mg per week. The patient must have a medical history that supports their use of WeGovy and must weigh at least 30 kg/m², or at least 27 kg/m² if they are suffering from obesity-related co-morbidities [5].

[1] https://drugpatentwatch.com/medicine/semaglutide

[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/214845Orig1s004bl.pdf

[3] https://www.fda.gov/Drugs/DrugSafety/ucm572876.htm

[4] https://www.drugs.com/ozempic.html

[5] https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/214845Orig1s003bl.pdf

Sources:

* drugpatentwatch.com
* FDA.gov
* Drugs.com